+

WO1996007739A3 - Interleukin-1 type 3 receptors - Google Patents

Interleukin-1 type 3 receptors Download PDF

Info

Publication number
WO1996007739A3
WO1996007739A3 PCT/US1995/012037 US9512037W WO9607739A3 WO 1996007739 A3 WO1996007739 A3 WO 1996007739A3 US 9512037 W US9512037 W US 9512037W WO 9607739 A3 WO9607739 A3 WO 9607739A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptors
interleukin
type
expressing
nucleic acid
Prior art date
Application number
PCT/US1995/012037
Other languages
French (fr)
Other versions
WO1996007739A2 (en
Inventor
Timothy W Lovenberg
Tilman Oltersdorf
Chen W Liaw
William Clevenger
Errol B Desouza
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Priority to AU36805/95A priority Critical patent/AU705595B2/en
Priority to JP8509726A priority patent/JPH10508743A/en
Priority to EP95934482A priority patent/EP0779923A2/en
Publication of WO1996007739A2 publication Critical patent/WO1996007739A2/en
Publication of WO1996007739A3 publication Critical patent/WO1996007739A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides isolated nucleic acid molecules encoding soluble and membrane bound forms of Interleukin-1 Type 3 receptors, as well as recombinant expression vectors and host cells suitable for expressing such receptors.
PCT/US1995/012037 1994-09-09 1995-09-11 Interleukin-1 type 3 receptors WO1996007739A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU36805/95A AU705595B2 (en) 1994-09-09 1995-09-11 Interleukin-1 type 3 receptors
JP8509726A JPH10508743A (en) 1994-09-09 1995-09-11 Interleukin-1 type 3 receptor
EP95934482A EP0779923A2 (en) 1994-09-09 1995-09-11 Interleukin-1 type 3 receptors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30395794A 1994-09-09 1994-09-09
US08/303,957 1994-09-09

Publications (2)

Publication Number Publication Date
WO1996007739A2 WO1996007739A2 (en) 1996-03-14
WO1996007739A3 true WO1996007739A3 (en) 1996-04-18

Family

ID=23174426

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/012037 WO1996007739A2 (en) 1994-09-09 1995-09-11 Interleukin-1 type 3 receptors

Country Status (5)

Country Link
EP (1) EP0779923A2 (en)
JP (1) JPH10508743A (en)
AU (1) AU705595B2 (en)
CA (1) CA2199609A1 (en)
WO (1) WO1996007739A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7052881B2 (en) 1995-06-15 2006-05-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US9228205B2 (en) 2000-11-15 2016-01-05 Crucell Holland B.V. Complementing cell lines

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
CA2306455A1 (en) * 1997-10-15 1999-04-22 Schering Corporation Human receptor proteins; related reagents and methods
US6326472B1 (en) 1997-10-15 2001-12-04 Schering Corporation Human receptor proteins; related reagents and methods
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
FR2804028B1 (en) * 2000-01-21 2004-06-04 Merial Sas IMPROVED DNA VACCINES FOR PENSION ANIMALS
AU2001233212A1 (en) 2000-02-02 2001-08-14 Schering Corporation Mammalian cytokines; receptors; related reagents and methods
US7235233B2 (en) 2000-09-26 2007-06-26 Crucell Holland B.V. Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
CN100497639C (en) 2002-04-25 2009-06-10 克鲁塞尔荷兰公司 Means and methods for the production of adenovirus vectors
BR112020027015A2 (en) 2018-07-16 2021-04-06 Regeneron Pharmaceuticals, Inc. ISOLATED ANTIGEN BINDING PROTEIN, ANTIBODY OR ANTIGEN BINDING FRAGMENT OF THE SAME, COMPLEX, METHOD TO PRODUCE AN ANTIGEN BINDING PROTEIN, ANTIGEN, ANTIGEN, HYDROTHEYTHEATING, POLYTHEOLOGY, HYDROTHEYTHEATING PROTEIN KIT, PHARMACEUTICAL COMPOSITION, CONTAINER OR INJECTION DEVICE, AND METHOD FOR TREATING OR PREVENTING DISEASES

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993019777A1 (en) * 1992-03-30 1993-10-14 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
WO1994020517A1 (en) * 1993-03-08 1994-09-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Gene transfer for treating a connective tissue of a mammalian host
EP0623674A1 (en) * 1987-11-25 1994-11-09 Immunex Corporation Interleukin-1 receptors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0623674A1 (en) * 1987-11-25 1994-11-09 Immunex Corporation Interleukin-1 receptors
WO1993019777A1 (en) * 1992-03-30 1993-10-14 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
WO1994020517A1 (en) * 1993-03-08 1994-09-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Gene transfer for treating a connective tissue of a mammalian host

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7052881B2 (en) 1995-06-15 2006-05-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US7105346B2 (en) 1995-06-15 2006-09-12 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US9228205B2 (en) 2000-11-15 2016-01-05 Crucell Holland B.V. Complementing cell lines

Also Published As

Publication number Publication date
WO1996007739A2 (en) 1996-03-14
AU705595B2 (en) 1999-05-27
EP0779923A2 (en) 1997-06-25
AU3680595A (en) 1996-03-27
JPH10508743A (en) 1998-09-02
CA2199609A1 (en) 1996-03-14

Similar Documents

Publication Publication Date Title
HK1040401A1 (en) Isolated nucleic acid molecules which encode t cell inducible factors (tifs), the proteins encoded, and uses thereof
WO1996007739A3 (en) Interleukin-1 type 3 receptors
WO1996034107A3 (en) Antiviral proteins, dna coding sequences therefor, and uses thereof
CA2258502A1 (en) Modified factor viii
WO2000005367A3 (en) Human proteins having hydrophobic domains and dnas encoding these proteins
EP1559776A3 (en) Non-toxic, non-toxigenic, non-pathogenic Fusarium expression system and promoters and terminators for use therein
CA2315274A1 (en) Polypeptides having aminopeptidase activity and nucleic acids encoding same
CA2200423A1 (en) Novel estrogen receptor
WO1998021343A8 (en) Genes encoding telomerase proteins
WO1995034651A3 (en) Corticotropin-releasing factor2 receptors
WO1996023066A3 (en) Prostaglandin receptor, dp
AU7489098A (en) Polypeptides having aminopeptidase activity and nucleic acids encoding same
WO2000029448A3 (en) Human proteins having hydrophobic domains and dnas encoding these proteins
CA2336261A1 (en) Cyclin e2 genes and proteins
CA2173102A1 (en) Dna sequence coding for a bmp receptor
AU5559499A (en) Identification of the gene causing the mouse scurfy phenotype and its human ortholog
CA2204151A1 (en) Cdna encoding a bmp type ii receptor
AU6978096A (en) Dna encoding an sh2-inositol phosphatase, an shc-binding protein
AU4375493A (en) Isolated protein receptors, antibodies which bind thereto, nucleic acid sequence coding therefor, and uses thereof
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
WO2000018909A3 (en) NUCLEIC ACIDS AND PROTEINS FROM $i(CENARCHAEUM SYMBIOSUM)
WO1994019464A3 (en) Human dna sequence encoding a kidney atp-dependent potassium channel
AU3711597A (en) A novel galanin receptor
WO1999009182A3 (en) Rab proteins
AU1183200A (en) Novel gene encoding brain-specific membrane protein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU JP KG KP KR KZ LK LR LT LV MD MG MN MX NO NZ PL RO RU SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2199609

Country of ref document: CA

Ref country code: CA

Ref document number: 2199609

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1995934482

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995934482

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995934482

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载